Clinical features, therapeutic choice and response by phototype in psoriasis: analysis of the French PsoBioTeq cohort

• Published in: Clinical and experimental dermatology 2023-10, Vol.48 (11), p.1238-1246
• Main Authors: Salle, Romain, Tubach, Florence, Arlegui, Hugo, Curmin, Raphaëlle, Viguier, Manuelle, Beylot-Barry, Marie, Dupuy, Alain, Beneton, Nathalie, Joly, Pascal, De Rycke, Yann, Jullien, Denis, Mahé, Emmanuel, Paul, Carle, Richard, Marie-Aleth, Bachelez, Hervé, Zago, Marilyn, Chosidow, Olivier, Sbidian, Émilie
• Format: Article
• Language: English
• Subjects: Life Sciences
• ISSN: 0307-6938; 1365-2230
• DOI: 10.1093/ced/llad233

Little is known about phototype and the response to systemic treatment in psoriasis. To assess the characteristics of psoriasis, the therapeutic choice and its efficacy according to phototype. We included patients from the PsoBioTeq cohort initiating a first biologic. Patients were classified according to their phototype. The evaluation included disease characteristics, choice of the initial biologic and therapeutic response at 12 months based on PASI 90 and DLQI 0/1. Of the 1400 patients included, 423 (30.2%), 904 (64.6%) and 73 (5.2%) were in the phototype I-II, III-IV and V-VI groups, respectively. The V-VI group had a higher initial DLQI, more frequently initiated ustekinumab. Patients in the phototype V-VI group maintained the first sequence of biologic as the other phototype groups, even though the proportion of patients reaching the PASI 90 and DLQI 0/1 at 12 months was lower in this group than other groups. Patient phototype seems associated with quality of life and choice of the initial biologic in psoriasis. Phototype V-VI group less frequently switched treatments than did the other groups when the response was not efficient.